Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
Primary Purpose
Infant, Low Birth Weight, Hyperglycemia
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
alanine
amino acids
glucagon
glucose
glutamine
glycerol
insulin
leucine
lipids
urea
Sponsored by
About this trial
This is an interventional treatment trial for Infant, Low Birth Weight focused on measuring endocrine disorders, hyperglycemia, low birth weight, neonatal disorders, rare disease
Eligibility Criteria
Clinically stable, very low birth weight infants (750-1,500 grams) Normal blood glucose values OR Blood glucose greater than 175 mg/dL No prior insulin No sepsis Oxygen supply less than 30% Normal acid base status No malformation No discernible diseases
Sites / Locations
- Baylor College of MedicineRecruiting
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00005889
First Posted
June 2, 2000
Last Updated
June 23, 2005
Sponsor
National Center for Research Resources (NCRR)
Collaborators
Baylor College of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT00005889
Brief Title
Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
Official Title
Study of Gluconeogenesis in Very Low Birth Weight Infants Receiving Total Parenteral Nutrition
Study Type
Interventional
2. Study Status
Record Verification Date
December 2003
Overall Recruitment Status
Unknown status
Study Start Date
October 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Center for Research Resources (NCRR)
Collaborators
Baylor College of Medicine
4. Oversight
5. Study Description
Brief Summary
RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known.
PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
Detailed Description
PROTOCOL OUTLINE: Patients are assigned to one of 6 study groups.
Patients receive infusions of stable isotope tracers: [15N]urea IV beginning at -12 hours and continuing over 22 hours to measure protein oxidation; [U-13C]glucose IV beginning at zero hour and continuing over 10 hours to measure glucose appearance rate and gluconeogenesis; [2-13C]glycerol IV over 10 hours to measure lipolysis; and [1-C]leucine IV over 10 hours to measure proteolysis. Blood samples are obtained before the start of the urea tracer infusion; before the start of the glucose, glycerol, and leucine tracer infusions; and at study hours 4, 4.5, 5, 9, 9.5, and 10. Blood glucose is measured hourly, and patients receive glucose IV if blood glucose falls below 40 mg/dL.
Group I: Patients are randomized to one of two study arms. Arm I: Patients receive standard total parenteral nutrition (TPN), except the [U-13C]glucose is substituted for a portion of the glucose. Arm II: The infusions of lipids (Intralipid) and amino acids (TrophAmine) are discontinued at study hour zero. The infusion rate of natural glucose will be reduced during the first hour, and thereafter discontinued.
Group II: Patients are randomized to receive either TrophAmine or Intralipid IV over the last 5 hours of the study.
Group III: Patients are randomized to receive one of two different doses of glycerol IV over the last 5 hours of the study.
Group IV: Patients are randomized to receive either glutamine or alanine IV over the last 5 hours of the study.
Group V: Patients receive glucagon IV for 24 hours prior to study. Patients are then randomized to receive glucagon IV with either IV glucose alone or with Intralipid and TrophAmine IV.
Group VI: Patients who are hyperglycemic receive TPN and [U-13C]glucose as in group I, arm I, over 14 hours, and regular insulin IV at 10 hours, followed by an IV infusion of carbohydrate. Blood samples obtained between hours 4 and 5 are omitted, and are drawn instead between hours 13 and 14.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infant, Low Birth Weight, Hyperglycemia
Keywords
endocrine disorders, hyperglycemia, low birth weight, neonatal disorders, rare disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Enrollment
96 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
alanine
Intervention Type
Drug
Intervention Name(s)
amino acids
Intervention Type
Drug
Intervention Name(s)
glucagon
Intervention Type
Drug
Intervention Name(s)
glucose
Intervention Type
Drug
Intervention Name(s)
glutamine
Intervention Type
Drug
Intervention Name(s)
glycerol
Intervention Type
Drug
Intervention Name(s)
insulin
Intervention Type
Drug
Intervention Name(s)
leucine
Intervention Type
Drug
Intervention Name(s)
lipids
Intervention Type
Drug
Intervention Name(s)
urea
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Days
Maximum Age & Unit of Time
6 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Clinically stable, very low birth weight infants (750-1,500 grams)
Normal blood glucose values OR Blood glucose greater than 175 mg/dL
No prior insulin
No sepsis Oxygen supply less than 30% Normal acid base status
No malformation
No discernible diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Agneta L. Sunehag
Organizational Affiliation
Baylor College of Medicine
Official's Role
Study Chair
Facility Information:
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Agneta L. Sunehag
Phone
713-798-6725
Email
asunehag@bcm.tmc.edu
12. IPD Sharing Statement
Citations:
PubMed Identifier
33006765
Citation
Amari S, Shahrook S, Namba F, Ota E, Mori R. Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD012273. doi: 10.1002/14651858.CD012273.pub2.
Results Reference
derived
Learn more about this trial
Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
We'll reach out to this number within 24 hrs